Filing Details

Accession Number:
0001439222-23-000010
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-02-01 16:04:33
Reporting Period:
2023-01-30
Accepted Time:
2023-02-01 16:04:33
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1439222 Agios Pharmaceuticals Inc. AGIO Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1578200 P David Schenkein C/O Agios Pharmaceuticals, Inc.
88 Sidney Street
Cambridge MA 02139
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-01-30 20,000 $9.05 137,879 No 4 M Direct
Common Stock Disposition 2023-01-30 16,700 $29.22 121,179 No 4 S Direct
Common Stock Disposition 2023-01-30 3,300 $29.88 117,879 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock option (right to buy) Disposition 2023-01-30 20,000 $0.00 20,000 $9.05
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
96,363 2023-04-29 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 270,772 Indirect See footnote
Common Stock 79,082 Indirect See footnote
Footnotes
  1. This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
  2. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
  3. The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $28.69 to $29.69. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
  4. The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $29.71 to $30.32. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
  5. Shares held by David P. Schenkein 2004 Revocable Trust, of which the reporting person is trustee and beneficiary.
  6. Shares held by Amy P. Schenkein 2004 Revocable Trust, of which the reporting person's spouse is trustee and beneficiary.
  7. This option was originally granted on April 30, 2013 for the purchase of 136,363 shares of common stock. The option vests as to 50% of the underlying shares upon the achievement of a performance milestone, and as to the remaining 50% of upon the achievement of a second performance milestone. The Company's board of directors determined that the first performance milestone was achieved on December 3, 2015, resulting in the vesting of this option as to 68,181 shares. On January 26, 2017, the Company's board of directors determined that the second performance milestone was achieved, resulting in the vesting of this option as to the remaining 68,182 shares.